Abstract: The present invention relates to at least one botulinum neurotoxin for treatment of prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
Type:
Grant
Filed:
April 27, 2009
Date of Patent:
July 22, 2014
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Christine Favre, Michel Auguet, Piere-Etienne Chabrier De Lassauniere
Abstract: The present invention relates to novel analogues of insulin-like growth factor-1 (IGF-1), pharmaceutical compositions containing said analogues, and the use of said analogues for treatment of IGF-1-receptor mediated conditions, such as short stature, diabetes therapy, neurodegenerative disease treatment, and cartilage repair. More particularly, the present invention relates to novel analogues of IGF-1 having an amino acid substitution at position 59, e.g., (Asn59)hIGF-1(1-70)-OH (SEQ ID NO:1), and other substitution(s) as defined herein.
Type:
Grant
Filed:
July 22, 2010
Date of Patent:
June 24, 2014
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Zheng Xin Dong, Nicholas C. Prairie, Maria L. Ufret, Jundong Zhang, Deborah M. Rothman, Jeanne Mary Comstock
Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.
Abstract: The present invention relates to at least one botulinum neurotoxin for treatment or prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
Type:
Application
Filed:
February 7, 2014
Publication date:
June 5, 2014
Applicant:
IPSEN PHARMA S.A.S.
Inventors:
Christine FAVRE, Michel AUGUET, Piere-Etienne CHABRIER DE LASSAUNIERE
Abstract: A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, H-Inp-D-Bal-D-Trp-Phe-Apc-NH2 (SEQ ID NO:73) or other suitable ghrelin agonist, to counteract the catabolic effects of dexamethasone and other natural glucocorticoids.
Type:
Grant
Filed:
November 2, 2011
Date of Patent:
June 3, 2014
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Giovanni Tulipano, Andrea Giustina, Zheng Xin Dong, Michael DeWitt Culler
Abstract: The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.
Abstract: The present invention relates to a sustained-release drug composition consisting essentially of microparticles of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection formulation comprising the sustained-release drug composition suspended in an injection medium.
Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.
Type:
Application
Filed:
October 31, 2013
Publication date:
May 1, 2014
Applicant:
IPSEN PHARMA S.A.S.
Inventors:
ZHENG XIN DONG, YEELANA SHEN, SUN HYUK KIM
Abstract: The present application relates to novel imidazolidine-2,4-dione derivatives of the general formula (I), where R1, R2, R3, R4, X, and Y are variables. Said materials have an antiproliferative activity. They are particularly useful for treating pathological conditions and diseases, such as cancer, that are linked to abnormal cell proliferation. The invention also relates to pharmaceutical compositions containing said materials and to the use thereof for preparing a drug.
Abstract: The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.
Type:
Grant
Filed:
April 21, 2004
Date of Patent:
April 29, 2014
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Zheng Xin Dong, Yeelena Shen, Jeanne Mary Comstock, Sun H. Kim
Abstract: The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound.
Type:
Grant
Filed:
March 26, 2012
Date of Patent:
April 8, 2014
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Delphine Delahaye, Christian Diolez, Alain Rolland, Francis Diancourt, Gérard Coquerel, Damien Martins, Barry Victor Lloyd Potter, Lok Wai Lawrence Woo
Abstract: The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound.
Type:
Application
Filed:
August 1, 2013
Publication date:
February 27, 2014
Applicant:
Ipsen Pharma S.A.S.
Inventors:
Nathalie MONDOLY, Bertrand Poirot, Anne Brochard, Joël Richard, Delphine Delahaye, Christian Diolez, Alain Rolland, Francis Diancourt, Gérard Coquerel, Damien Martins, Julie Linol, Ophélie Houssin, Marie-Noêlle Petit, Barry, Victor, Lloyd Potter, Lok, Wai Lawrence Woo
Abstract: The present invention relates to a composition containing at least one amidine derivative or carboxamide derivative of general formula (I) or (A) in combination with at least one compound chosen from steroids, corticoids or corticosteroids, wherein said composition is suitable for the preparation of a medicament.
Type:
Grant
Filed:
March 6, 2007
Date of Patent:
February 4, 2014
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Bernadette Pignol, Serge Auvin, Dennis Bigg, Pierre-Etienne Chabrier de Lassauniere
Abstract: The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.
Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
Type:
Application
Filed:
September 12, 2013
Publication date:
January 9, 2014
Applicant:
Ipsen Pharma S.A.S.
Inventors:
Zheng Xin DONG, Daniel B. DEOLIVEIRA, Jeanne Mary COMSTOCK
Abstract: The subject matter of the present application is novel imidazolidine-2,4-dione derivatives. These products have an antiproliferative activity. They are particularly advantageous for treating pathological conditions and diseases associated with abnormal cell proliferation, such as cancers. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for preparing a medicament.
Type:
Grant
Filed:
April 16, 2010
Date of Patent:
January 7, 2014
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Dennis Bigg, Serge Auvin, Christophe Lanco, Grégoire Prevost
Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of dyslipidemia and associated complications such as alcoholic and non-alcoholic fatty liver disease.
Type:
Application
Filed:
August 21, 2013
Publication date:
December 12, 2013
Applicant:
Ipsen Pharma, S. A. S.
Inventors:
Heather A. HALEM, Michael DeWitt CULLER
Abstract: The invention relates to a method for preparing linear polymers having an amide end or having a star architecture comprising an amide core, by means of a ring opening using lactide and glycolide monomers or a lactide monomer ring in the presence of a catalyst, wherein the method includes the steps of: (i) reacting the excess monomer(s) with an initiator in a solvent, said initiator being selected from among an amine and an amino alcohol, given that the initiator has at least one primary or secondary amine function; (ii) adding a catalyst, said catalyst being a non-nucleophilic base and including at least one neutral sp2 nitrogen atom; and (iii) neutralizing the reaction mixture. Said novel method is particularly advantageous in that it can be easily monitored and enables better modulation of the polymers, and thus of the properties thereof, than the methods of the prior art. The invention also relates to novel polymers that are obtainable by means of said method.
Type:
Application
Filed:
November 14, 2011
Publication date:
November 28, 2013
Applicant:
IPSEN PHARMA S.A.S.
Inventors:
Didier Bourissou, Blanca Martin-Vaca, Aurélie Alba, Roland Cherif-Cheikh, Anne-Paula De Sousa Delgado
Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
Type:
Grant
Filed:
May 23, 2008
Date of Patent:
October 22, 2013
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Zheng Xin Dong, Daniel B. Deoliveira, Jeanne Mary Comstock
Abstract: The present invention relates to the use of a system composed of a base and of a sulphonamide, as a catalyst for the ring-opening (co)polymerization of lactones. The present invention also relates to novel sulphonamides and to a process for the ring-opening (co)polymerization of lactones comprising the use of sulphonamides in combination with a base as a catalytic system.
Type:
Grant
Filed:
April 29, 2009
Date of Patent:
October 22, 2013
Assignee:
Ipsen Pharma S.A.S.
Inventors:
Didier Bourissou, Blanca Martin-Vaca, Aurelie Alba, Roland Cherif-Cheikh, Anne-Paula De Sousa Delgado